PENTALINK INJECTION 40 mg
Family: Proton Pump Inhibitor (PPI).
Dosage Form: Powder for Solution for Injection / Intravenous Infusion.
Strength: Each vial contains Pantoprazole 40 mg.
Product Description: PENTALINK Injection 40 mg contains pantoprazole, a potent gastric acid-suppressing agent used in the management of selected acid-related gastrointestinal disorders. It reduces gastric acid secretion by inhibiting the proton pump in the stomach's parietal cells. The injectable formulation provides an alternative when oral administration is temporarily unsuitable or when intravenous treatment is clinically indicated.
Indications: PENTALINK is indicated for the short-term treatment of gastroesophageal reflux disease (GERD) associated with erosive esophagitis when intravenous therapy is appropriate. It is also used for pathological gastric acid hypersecretion, including Zollinger–Ellison syndrome, according to the approved product information. The specific indications should be confirmed against local product registration.
Mechanism of Action: Pantoprazole selectively inhibits the gastric H+/K+-ATPase enzyme system, commonly known as the proton pump, in gastric parietal cells. This blocks the final stage of gastric acid production, reducing both basal and stimulated acid secretion and helping control acid-related irritation and damage.
Clinical Benefits: PENTALINK helps reduce excessive gastric acid production, supports healing of acid-related esophageal inflammation, and helps control symptoms associated with acid reflux. Its intravenous formulation is useful for patients who cannot temporarily take oral medication or require parenteral treatment under medical supervision.
Key Benefits: Effective suppression of gastric acid secretion; supports healing of erosive esophagitis; helps manage pathological acid hypersecretion; provides an intravenous treatment option when oral therapy is unsuitable; and offers convenient once-daily dosing for many approved adult indications.
Dosage and Administration: For adults with GERD associated with erosive esophagitis, the commonly approved dosage is Pantoprazole 40 mg once daily by intravenous injection or infusion for a limited treatment period, generally up to 10 days under standard product labeling. The dose and duration for pathological hypersecretory conditions may differ and require individualized medical management. Treatment should be changed to appropriate oral therapy as soon as the patient can take medication by mouth. The injection must be reconstituted and administered by a qualified healthcare professional according to the approved package insert. Do not administer by an unapproved route.
Contraindications: PENTALINK should not be used in patients with known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation. Concomitant use with rilpivirine-containing medicines is contraindicated under standard proton pump inhibitor labeling.
Possible Side Effects: Common adverse effects may include headache, diarrhea, nausea, abdominal discomfort, vomiting, and injection-site reactions. Less common but serious reactions can include severe allergic reactions, kidney inflammation, and severe or persistent diarrhea. Prolonged or repeated proton pump inhibitor treatment may be associated with additional risks, including low magnesium, vitamin B12 deficiency, and fractures in susceptible patients.
Drug Interactions: Pantoprazole may affect medicines whose absorption depends on gastric acidity. Concomitant use with rilpivirine-containing products is contraindicated. Monitor carefully when used with warfarin, high-dose methotrexate, or other medicines with clinically significant interaction potential. Patients should inform their healthcare professional about all prescription medicines, over-the-counter products, and supplements they use.
Use During Pregnancy: Use during pregnancy should be based on an assessment of clinical need, expected benefit, and potential risk. Medical advice is recommended before administration.
Breastfeeding: Pantoprazole treatment during breastfeeding should be assessed by a healthcare professional based on the mother's clinical condition and the available product information.
Warnings and Precautions: Use with caution in patients with severe liver disease or a history of hypersensitivity to proton pump inhibitors. Persistent symptoms, unexplained weight loss, difficulty swallowing, recurrent vomiting, or gastrointestinal bleeding require appropriate medical evaluation. Acid suppression may increase susceptibility to certain gastrointestinal infections. Prolonged treatment should be reviewed periodically by the prescribing healthcare professional.
Storage: Store according to the approved product packaging and manufacturer’s instructions. Protect from light when specified on the label. Follow the product-specific instructions for reconstitution, use, and disposal; keep out of reach of children.
Product Summary: PENTALINK Injection 40 mg is an intravenous pantoprazole formulation designed to suppress gastric acid secretion in selected acid-related gastrointestinal disorders. Its targeted proton pump inhibition supports the management of erosive esophagitis and pathological acid hypersecretion when injectable treatment is clinically appropriate.
Company: LINCOLN